Основная статистика
| LEI | 529900TC35UPZQYRKW13 |
| CIK | 1560241 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to G1 Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| November 13, 2024 |
GTHX / G1 Therapeutics, Inc. / Beryl Capital Management LLC Passive Investment SC 13G/A 1 g1therapeutics13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* G1 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| September 30, 2024 |
As filed with the Securities and Exchange Commission on September 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 18, 2024 |
AMENDED AND RESTATED G1 THERAPEUTICS, INC. * * * * * ARTICLE 1 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF G1 THERAPEUTICS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01 Registered Office. The registered office of G1 Therapeutics, Inc. (the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02 Other Offices. The Corporation may also have offices at such other places both within and without the State of Delawar |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION G1 THERAPEUTICS, INC. Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF G1 THERAPEUTICS, INC. FIRST. The name of the corporation is G1 Therapeutics, Inc. SECOND. The address of the corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, DE 19808, County of New Castle. The name of its registered agent at such address is Corporation Service Company. THIRD. Th |
|
| September 18, 2024 |
Gthx-form25 |
|
| September 18, 2024 |
Exhibit 99.1 Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, DENMARK and RESEARCH TRIANGLE PARK, NC, September 18, 2024 – Pharmacosmos A/S, a leader in th |
|
| September 18, 2024 |
Exhibit (a)(5)(E) Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U. |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 G1 THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38096 26-3648180 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) G1 THERAPEUTICS, INC. (Name of Subject Company (Issuer)) GENESIS MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of PHARMACOSMOS A/S (Parent of Offeror) (Names of Filing Persons (identifying statu |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
SC 14D9/A 1 d823822dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Tit |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 18, 2024 |
As filed with the Securities and Exchange Commission on September 18, 2024 As filed with the Securities and Exchange Commission on September 18, 2024 Registration No. |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSI |
|
| September 5, 2024 |
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period Exhibit (a)(5)(D) Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period HOLBAEK, DENMARK and RESEARCH TRIANGLE PARK, NC, September 5, 2024 – Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 362 |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) G1 THERAPEUTICS, INC. (Name of Subject Company (Issuer)) GENESIS MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of PHARMACOSMOS A/S (Parent of Offeror) (Names of Filing Persons (identifying statu |
|
| August 20, 2024 |
AMENDMENT NO. 1 TO MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (e)(3) AMENDMENT NO. 1 TO MUTUAL CONFIDENTIALITY AGREEMENT This Amendment No. 1 to Mutual Confidentiality Agreement (the “Amendment”) is entered into by and between G1 Therapeutics, Inc., a Delaware corporation (“G1 Therapeutics”) and Pharmacosmos A/S (“Pharmacosmos”) and is effective as of July 11, 2024 (the “Effective Date”). WHEREAS, Pharmacosmos and G1 Therapeutics are parties to a Mut |
|
| August 20, 2024 |
Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of G1 THERAPEUTICS, INC. |
|
| August 20, 2024 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of G1 THERAPEUTICS, INC. |
|
| August 20, 2024 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Rule 14d-100) G1 THERAPEUTICS, INC. |
|
| August 20, 2024 |
Exhibit (e)(4) August 6, 2024 G1 Therapeutics, Inc. 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 Re: Exclusivity Agreement Dear Jack: Further to the negotiations between G1 Therapeutics, Inc. (the “Company”) and Pharmacosmos A/S (“Buyer”) and the contemplated acquisition of the Company by Buyer or an affiliate thereof, for good and valuable consideration (the receipt of which |
|
| August 20, 2024 |
Exhibit (d)(4) August 6, 2024 G1 Therapeutics, Inc. 700 Park Offices Drive, Suite 200 Research Triangle Park, NC 27709 Re: Exclusivity Agreement Dear Jack: Further to the negotiations between G1 Therapeutics, Inc. (the “Company”) and Pharmacosmos A/S (“Buyer”) and the contemplated acquisition of the Company by Buyer or an affiliate thereof, for good and valuable consideration (the receipt of which |
|
| August 20, 2024 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of G1 THERAPEUTICS, INC. |
|
| August 20, 2024 |
Exhibit (b)(1) 27P5-UN7U-HHNA Please note that this document is an English translation of the original Danish version prepared only for your convenience. |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company (Issuer)) GENESIS MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of PHARMACOSMOS A/S (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issu |
|
| August 20, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of G1 THERAPEUTICS, INC. |
|
| August 20, 2024 |
MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (e)(2) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (the ”Agreement”), effective as of February 6, 2024 (the “Effective Date”), by and between Pharmacosmos A/S, company registration number 15517085, located at Rørvangsvej 30, DK-4300 Holbæk, Denmark (“Pharmacosmos“) and G1 Therapeutics, Inc. |
|
| August 20, 2024 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| August 20, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 362 |
|
| August 20, 2024 |
AMENDMENT NO. 1 TO MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (d)(3) AMENDMENT NO. 1 TO MUTUAL CONFIDENTIALITY AGREEMENT This Amendment No. 1 to Mutual Confidentiality Agreement (the “Amendment”) is entered into by and between G1 Therapeutics, Inc., a Delaware corporation (“G1 Therapeutics”) and Pharmacosmos A/S (“Pharmacosmos”) and is effective as of July 11, 2024 (the “Effective Date”). WHEREAS, Pharmacosmos and G1 Therapeutics are parties to a Mut |
|
| August 20, 2024 |
MUTUAL CONFIDENTIALITY AGREEMENT Exhibit (d)(2) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (the ”Agreement”), effective as of February 6, 2024 (the “Effective Date”), by and between Pharmacosmos A/S, company registration number 15517085, located at Rørvangsvej 30, DK-4300 Holbæk, Denmark (“Pharmacosmos“) and G1 Therapeutics, Inc. |
|
| August 19, 2024 |
GTHX / G1 Therapeutics, Inc. / Beryl Capital Management LLC Passive Investment SC 13G 1 g1therapeutics13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* G1 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSIP Number) August 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company (Issuer)) GENESIS MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of Pharmacosmos A/S (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issu |
|
| August 14, 2024 |
1 G1 Townhall Meeting – August 2024 Introduction to Pharmacosmos Exhibit 99.1 1 G1 Townhall Meeting – August 2024 Introduction to Pharmacosmos 2 COMPL2023 - 003 - C - 210223 TOBIAS S. CHRISTENSEN President & CEO MSc Eng CLAES CHRISTIAN STRØM Executive Vice President, CCO MD, PhD, BBA JOSH FRANKLIN President, Pharmacosmos Therapeutics Inc., US 3 Pharmacosmos Introduction COMPL2023 - 003 - C - 210223 Our focus, ambition & solutions 4 COMPL2023 - 003 - C - 210223 |
|
| August 14, 2024 |
FAQ For G1 Therapeutics Employees Exhibit 99.2 FAQ For G1 Therapeutics Employees · Why did Pharmacosmos acquire the company? ○ We recognize the important benefits that Cosela brings to patients, and we believe that the expanded field presence realized through this acquisition will ensure that the product is available to more patients. · Why do we think we can leverage this opportunity? ○ G1 and Pharmacosmos Therapeutics are callin |
|
| August 8, 2024 |
EXHIBIT 10.5 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Terry Murdock, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively as the “Parties |
|
| August 8, 2024 |
Exhibit 99.1: Press Release dated August 8, 2024 Exhibit 99.1 G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA® (trilaciclib) - - Drove Double Digit Quarter-Over-Quarter Growth in COSELA Vial Volume and Net Revenu |
|
| August 8, 2024 |
EXHIBIT 10.6 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Perry, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively as the “Partie |
|
| August 8, 2024 |
Amendment to Employment Agreement by and between Monica R. Thomas and the Registrant effective as of EXHIBIT 10.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Monica R. Thomas, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively as the “Pa |
|
| August 8, 2024 |
pressrelease-2q24financi 1 G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Persons Filing Statement) COMMON STOCK PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 3621LQ109 (CUSIP Numb |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERA |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2024 |
EX-10.4 Exhibit 10.4 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John W. Umstead V, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively a |
|
| August 7, 2024 |
Fourth Amendment to Employment Agreement by and between the Company and Rajesh K. Malik EX-10.3 Exhibit 10.3 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT THIS FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Rajesh Malik, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively as the |
|
| August 7, 2024 |
Exhibit 99.3: G1 Investor FAQ, first used on August 7, 2024 EX-99.3 Exhibit 99.3 Investor FAQ Questions about the transaction 1) What was announced? a) G1 has agreed to be acquired by Pharmacosmos A/S, a global hematology and supportive care leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, for an equity value of approximately $405 million, or $7.15 per share in cash b) The combined t |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 (August 6, 2024) G1 Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38096 26-3648180 (State or Other Jurisdiction of Incorporation) ( |
|
| August 7, 2024 |
Exhibit 99.2: G1 Employee FAQ, first used on August 7, 2024 EX-99.2 Exhibit 99.2 Employee FAQ Questions about the transaction 1) What was announced? a) G1 has agreed to be acquired by Pharmacosmos A/S, a global hematology and supportive care leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, for approximately $405 million, or U.S. $7.15 per share in cash. b) The combined team will focu |
|
| August 7, 2024 |
Exhibit 99.8: G1 Email to certain partners of the Company on August 7, 2024 EX-99.8 Exhibit 99.8 Dear [Partner], I just wanted to reach out and personally make you aware of the transaction we announced this morning given our strong existing partnership. We look forward to continuing to work closely together on optimizing the value of our portfolio for patients. We believe this transaction puts us in a stronger place to achieve those objectives. On behalf of our entire G1 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 G1 THERAPEUTICS, INC. (Name of Subject Company (Issuer)) GENESIS MERGER SUB, INC. (Offeror) A wholly-owned subsidiary of Pharmacosmos A/S (Parent of Offeror) (Names of Filing Persons (identifying status as offeror, issu |
|
| August 7, 2024 |
EX-99.1 Exhibit 99.1 August 7, 2024 G1 Colleagues – Moments ago, we announced an agreement whereby Pharmacosmos will be acquiring G1 Therapeutics approximately $405 million, or U.S. $7.15 per share, in cash. The full press release we issued is attached. I wanted to provide each of you with background on the rationale for this agreement and give you a sense of who Pharmacosmos is. I’m sure you ha |
|
| August 7, 2024 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Persons Filing Statement) COMMON STOCK PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 3621LQ109 (CU |
|
| August 7, 2024 |
EX-99.1 Exhibit 99.1 Pharmacosmos Group to Acquire G1 Therapeutics - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos’ Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability of C |
|
| August 7, 2024 |
Joint press release of Pharmacosmos A/S and G1 Therapeutics, Inc. dated August 7, 2024. Exhibit 99.1 Pharmacosmos Group to Acquire G1 Therapeutics - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1’s COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - Pharmacosmos’ Significant Resources and Expertise in Hematology and Supportive Care to Maximize Availability COSELA for P |
|
| August 7, 2024 |
Exhibit 99.4: G1 Email to certain investors of the Company on August 7, 2024 EX-99.4 Exhibit 99.4 Subject: G1 Therapeutics to be Acquired by Pharmacosmos: No 2Q24 financial conference call Good morning, I’m reaching out to make sure you saw this morning’s announcement that G1 has entered into a definitive agreement to be acquired by Pharmacosmos A/S, a global supportive care leader in the development of innovative treatments for patients suffering from iron deficiency and |
|
| August 7, 2024 |
Exhibit 99.5: G1 Email to certain suppliers and vendors of the Company on August 7, 2024 EX-99.5 Exhibit 99.5 Dear Valued Partner, I’m reaching out to share some exciting news about G1 Therapeutics: We have reached an agreement to be acquired by Pharmacosmos, a global supportive care leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia. This combination is an important one, in that it will allow us to reach more pati |
|
| August 7, 2024 |
Amendment to Employment Agreement by and between Mark Avagliano and the Registrant effective as of EX-10.2 Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark Avagliano, an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively as t |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 G1 THERAPEUTICS, INC. (Name of Subject Company) G1 THERAPEUTICS, INC. (Name of Persons Filing Statement) COMMON STOCK PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 3621LQ109 (CUSIP Numb |
|
| August 7, 2024 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among PHARMACOSMOS A/S, GENESIS MERGER SUB, INC. and G1 THERAPEUTICS, INC. Dated as of August 6, 2024 TABLE OF CONTENTS ARTICLE I THE OFFER 2 Section 1.1. The Offer 2 Section 1.2. Company Consent; Schedule 14D-9 4 Section 1.3. Stockholder Lists 5 ARTICLE II THE MERGER 5 Section 2.1. The Merger 5 Section 2.2. Closing; Effective Time |
|
| August 7, 2024 |
Exhibit 99.7: G1 LinkedIn post, posted on August 7, 2024 EX-99.7 Exhibit 99.7 [The following communication was made available by G1 Therapeutics, Inc. on LinkedIn.] We are excited to announce that G1 has entered into a definitive agreement to be acquired by @Pharmacosmos for approximately $405 million. The combined company will be able to optimize the commercial reach to oncologists and expand the availability of our myeloprotection drug among patients |
|
| August 7, 2024 |
EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John E. Bailey, Jr., an individual (“Employee”) is made and entered into effective as of August 6, 2024. Employee and the Company may be individually referred to as a “Party” and collectively |
|
| August 7, 2024 |
Exhibit 99.6: G1 X Post, posted on August 7, 2024 EX-99.6 Exhibit 99.6 [The following post was made available by G1 Therapeutics, Inc. on X (formerly known as Twitter).] We are excited to announce that G1 has entered into an agreement to be acquired by Pharmacosmos to maximize the global availability of our myeloprotection drug among patients living with extensive stage small cell #lungcancer. Learn more: bit.ly/46zgk1H Cautionary Note Regarding |
|
| June 24, 2024 |
1 G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) - PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - - The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market - - G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 - - Management to Host Webcast and Conference Call Today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N. |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 1, 2024 |
EXHIBIT 10.7 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Monica Thomas, an individual (“Employee”). Employee and the Company may be individually referred to as a “Party” |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THER |
|
| May 1, 2024 |
EXHIBIT 10.6 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Terry Murdock, an individual (“Employee”). Employee and the Company may be individually referred to as a “Part |
|
| May 1, 2024 |
1 G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Achieved $14. |
|
| May 1, 2024 |
Malik and the Registrant effective as of April 1, 2024. EXHIBIT 10.5 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT THIS THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Rajesh Malik, an individual (“Employee”). Employee and the Company may be individually referred to as a “Party” |
|
| May 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission File |
|
| May 1, 2024 |
EXHIBIT 10.4 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Perry, an individual (“Employee”). Employee and the Company may be individually referred to as a “Party” |
|
| April 25, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| April 12, 2024 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 22, 2024 |
EXHIBIT 10.3 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark Avagliano, an individual (“Employee”). Employee and the Company may be individually referred to as a “Party |
|
| March 22, 2024 |
EXHIBIT 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John E. Bailey, Jr., an individual (“Employee”). Employee and the Company may be individually referred to as a “ |
|
| March 22, 2024 |
EXHIBIT 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of April 1, 2024 (the “Amendment Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John W. Umstead V, an individual (“Employee”). Employee and the Company may be individually referred to as a “Pa |
|
| February 28, 2024 |
Employment Agreement by and between the Registrant and EXHIBIT 10.29 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into effective as of May 22, 2023 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Monica R. Thomas (“Employee”). 1.EMPLOYMENT; DUTIES. The Company agrees to employ Employee as its General Counsel, and Employee agrees to accept such employment |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPEUT |
|
| February 28, 2024 |
pressrelease-4q23financi 1 G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights - Achieved $46. |
|
| February 28, 2024 |
EXHIBIT 10.28 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s Amended and Restated 2021 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restr |
|
| February 28, 2024 |
1 Therapeutics, Inc. Amended and Restated Clawback Policy EXHIBIT 10.25 G1 THERAPEUTICS, INC. AMENDED AND RESTATED CLAWBACK POLICY (Effective December 1, 2023) I. INTRODUCTION The Board of Directors (the “Board”) of G1 Therapeutics, Inc. (the “Company”), believes that it is in the best interests of the Company and its shareholders to create and maintain a corporate culture that emphasizes integrity and accountability and that reinforces the Company’s pay |
|
| February 28, 2024 |
orm of Restricted Stock Unit Agreement under the Amended and Restated 2017 EXHIBIT 10.27 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesti |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| February 21, 2024 |
GTHX / G1 Therapeutics, Inc. / ESHELMAN FREDRIC N - SC 13D/A Activist Investment SC 13D/A 1 d795034dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* G1 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 3621LQ109 (CUSIP Number) with a copy to: Fredric N. Eshelman Donald R. Reynolds, Esq. 319 North Third Street, Sui |
|
| February 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| February 12, 2024 |
EXHIBIT 99.1 1 G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee RESEARCH TRIANGLE PARK, N.C., February 12, 2024 – G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended co |
|
| January 8, 2024 |
1 42nd Annual J.P. Morgan Healthcare Conference Developing and Delivering Next Generation Therapies that Improve the Lives of People Living with Cancer Wednesday January 10, 1:30 PM PT 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend,“ |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission F |
|
| November 1, 2023 |
pressrelease-3q23financi G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights - Recognized Total Revenue of $12. |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 Form S-8 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THE |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| November 1, 2023 |
ment to Senior Advisor Agreement between Registrant and Mark A. Velleca, M.D., Exhibit 10.1 G1 THERAPEUTICS, INC. FIRST AMENDMENT TO SENIOR ADVISOR AGREEMENT This First Amendment to the Senior Advisor Agreement (the “First Amendment”) is deemed effective as of September 20, 2023 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark A. Velleca, M.D., Ph.D. (the “Advisor”). All capitalized terms used in this First Amendm |
|
| November 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) G1 Therapeutics, Inc. |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commissio |
|
| August 2, 2023 |
pressrelease-2q23financi G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights - Recognized Total Revenue of $42. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPEU |
|
| August 2, 2023 |
EXHIBIT 10.2 G1 THERAPEUTICS, INC. DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS Effective as of May 17, 2023 1. Plan The Board of Directors (the “Board”) of G1 Therapeutics, Inc. (the “Company”) hereby adopts this G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors (the “Plan”). 2. Effective Date and Plan Year The Plan is effective May 17, 2023 (the “Effective Date |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2023 |
2023 (File No. 001-38096), and incorporated herein by reference. a101-fifthamendmenttoloa EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[* * *]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT ( |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPE |
|
| May 3, 2023 |
Exhibit 10.3 Performance Based Restricted Stock Unit No. G1 Therapeutics, Inc. Performance Based Restricted Stock Unit Award Grant Notice Performance Based Restricted Stock Unit Award Grant under the Company’s Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Performance Based Restricted Stock Unit Award: 3. Ma |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission File |
|
| May 3, 2023 |
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights - Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC); Analysis No |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 14, 2023 |
SEC Response Letter April 14, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMM IS SION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 1, 2023 |
EXHIBIT 10.25 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into effective as of February 28, 2023 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John W. Umstead V (“Employee”). 1.EMPLOYMENT; DUTIES. The Company agrees to employ Employee as its Chief Financial Officer, and Employee agrees to accept s |
|
| March 1, 2023 |
pressrelease-4q22financi G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Achieved $31. |
|
| March 1, 2023 |
EXHIBIT 10.22 February 28, 2023 Jennifer K. Moses 109 Cedar Cliff Ct. Cary, NC 27518 Re: Senior Advisor Agreement Dear Jennifer: I am providing this letter agreement (the “Agreement”) to confirm the terms of your senior advisor engagement with G1 Therapeutics, Inc. (the “Company”). We appreciate all of your efforts and contributions to the Company, and look forward to entering into this engagement |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPEUTICS |
|
| March 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 13, 2023 |
EX-99.1 2 preserve1crcdata2x12x23.htm EX-99.1 Exhibit 99.1 G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) - PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During In |
|
| February 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 (February 9, 2023) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorpo |
|
| February 9, 2023 |
GTHX / G1 Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0960-g1therapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: G1 Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 3621LQ109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to design |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission F |
|
| January 9, 2023 |
EX-99.1 2 a2023jpmfinal2022-01x06.htm EX-99.1 1 41st Annual J.P. Morgan Healthcare Conference Wednesday January 11, 1:30 PM PT Advancing our Mission to Improve the Lives of those Affected by Cancer 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate |
|
| December 6, 2022 |
GTHX / G1 Therapeutics Inc / JPMORGAN CHASE & CO - FILING G1 THERAPEUTICS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* G1 THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 21, 2022 |
G1 Therapeutics Announces Pricing of Offering of Common Stock EX-99.1 4 d389175dex991.htm EX-99.1 Exhibit 99.1 G1 Therapeutics Announces Pricing of Offering of Common Stock RESEARCH TRIANGLE PARK, N.C., November 17, 2022 (GLOBE NEWSWIRE) – G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the pricing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per shar |
|
| November 21, 2022 |
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-257640 Prospectus supplement (to Prospectus dated February 23, 2022) 7,700,000 Shares Common Stock We are offering 7,700,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “GTHX.” On November 17, 2022, the last reported sale price of our common stock on The Nasd |
|
| November 21, 2022 |
EX-1.1 Exhibit 1.1 Execution Version 7,700,000 Shares G1 THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT November 17, 2022 COWEN AND COMPANY, LLC RAYMOND JAMES & ASSOCIATES, INC. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Raymond James & Associates, Inc. 880 Carillon Parkway St. Petersburg, Florida 33716 Dear M |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| November 17, 2022 |
Subject to completion, dated November 17, 2022 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-257640 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38096 G1 THERAPEUTICS, INC. |
|
| November 2, 2022 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[* * *]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), date |
|
| November 2, 2022 |
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC) - Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - RESEARCH TRIANGLE PARK, N. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| November 2, 2022 |
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights - Achieved $23. |
|
| August 3, 2022 |
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights - Achieved $8. |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38096 G1 THERAPEUTICS, INC. |
|
| August 3, 2022 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[* * *]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated |
|
| July 27, 2022 |
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors RESEARCH TRIANGLE PARK, N.C., July 25, 2022 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. ?Ned? Sharpless, M.D., to its Board of Directors. For nearly 30 years, Dr. Sharpless has been committed to the fight against cancer, including serving as |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 (July 27, 2022) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 (June 23, 2022) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| June 28, 2022 |
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors EXHIBIT 99.1 G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors RESEARCH TRIANGLE PARK, N.C., June 28, 2022 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life |
|
| June 24, 2022 |
Exhibit 99.3 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company?s Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vestin |
|
| June 24, 2022 |
Exhibit 99.9 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company?s Amended and Restated 2021 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restri |
|
| June 24, 2022 |
G1 Therapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan Exhibit 99.7 G1 THERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Approved and adopted by the Board on March 10, 2022) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this G1 Therapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan, have the following meanings: Administrator means |
|
| June 24, 2022 |
EX-99.2 4 d283968dex992.htm EX-99.2 Exhibit 99.2 Option No. G1 THERAPEUTICS, INC. Stock Option Grant Notice Stock Option Grant under the Company’s Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) pri |
|
| June 24, 2022 |
As filed with the Securities and Exchange Commission on June 24, 2022 As filed with the Securities and Exchange Commission on June 24, 2022 Registration No. |
|
| June 24, 2022 |
Exhibit 99.10 Option No. G1 THERAPEUTICS, INC. Non-Qualified Stock Option Grant Notice 1. Name and Address of Participant: Andrew Perry 200 West Barbee Chapel Road Chapel Hill, North Carolina 27517 2. Date of Option Grant: August 16, 2021 3. Maximum Number of Shares for which this Option is exercisable: 300,000 4. Exercise (purchase) price per share: $14.03 5. Option Expiration Date: August 16, 20 |
|
| June 24, 2022 |
Exhibit 99.6 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company?s 2021 Sales Force Inducement Equity Incentive Plan 1.??Name and Address of Participant: 2.??Date of Grant of Restricted Stock Unit Award: 3.??Maximum Number of Shares underlying Restricted Stock Unit Award: 4.??Vesting of Award: This Restricted |
|
| June 24, 2022 |
Exhibit 99.8 Option No. G1 THERAPEUTICS, INC. Stock Option Grant Notice Non-Qualified Stock Option Grant under the Company?s Amended and Restated 2021 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Maximum Number of Shares for which this Option is exercisable: 4. Exercise (purchase) price per share: 5. Option Expiration Date: 6. Vesting Start Date: |
|
| June 24, 2022 |
Exhibit 99.5 Option No. G1 THERAPEUTICS, INC. Stock Option Grant Notice Non-Qualified Stock Option Grant under the Company?s 2021 Sales Force Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Maximum Number of Shares for which this Option is exercisable: 4. Exercise (purchase) price per share: 5. Option Expiration Date: 6. Vesting Start Date: 7. Vesti |
|
| June 24, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) G1 Therapeutics, Inc. |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 (June 23, 2022) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 4, 2022 |
Exhibit 10.1 G1 THERAPEUTICS, INC. AMENDED AND RESTATED 2021 INDUCEMENT EQUITY INCENTIVE PLAN (Approved and adopted by the Board on March 10, 2022) 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this G1 Therapeutics, Inc. Amended and Restated 2021 Inducement Equity Incentive Plan, have the following meanings: Administrator means |
|
| May 4, 2022 |
EX-99.1 2 d335902dex991.htm EX-99.1 Exhibit 99.1 G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights - Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Fully Deployed G1’s COSELA Sales Team as of Mid-February 2022 - - Confirmed Expected Timelines for Initial Result |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission File |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 23, 2022 |
Exhibit 10.29 Execution Version EAST\188323058.5 G1 THERAPEUTICS, INC. COMMON STOCK (par value $0.0001 per share) SALES AGREEMENT February 23, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: G1 Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 23, 2022 Registration No. |
|
| February 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) G1 Therapeutics, Inc. |
|
| February 23, 2022 |
Exhibit 10.7 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[* * *]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. MUTUAL TERMINATION, RELEASE, AND SETTLEMENT AGREEMENT by and between G1 THERAPEUTICS, INC. and BOEHRINGER INGELHEIM PHARMACEU |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2022 POSASR 1 d300949dposasr.htm POSASR Table of Contents As filed with the Securities and Exchange Commission on February 23, 2022 Registration No. 333-257640 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 G1 Therapeutics, Inc. (Exact name of registrant as specified in its charte |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| February 23, 2022 |
Description of Securities of the Registrant. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated by-laws are summaries of material terms and provisions and are qualified by reference to our amended and restated certif |
|
| February 23, 2022 |
Exhibit 99.1 G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights - Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA? (trilaciclib) - - Completed Hiring, Training, and Deployment of G1?s COSELA Sales Team - - Announced That Initial Results from Phase 3 Trial of Trilaci |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPEUTICS |
|
| February 10, 2022 |
GTHX / G1 Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: G1 Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 3621LQ109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 21, 2022 |
GTHX / G1 Therapeutics Inc / JPMORGAN CHASE & CO - FILING G1 THERAPEUTICS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* G1 THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2022 |
Optimizing Chemotherapy, Advancing Survival 40th Annual J.P. Morgan Healthcare Conference January 10-13, 2022 Presentation time: Wednesday January 12, 1:30 PM ET Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar e |
|
| December 16, 2021 |
Exhibit 99.1 G1 Therapeutics Announces Expansion of COSELA? (Trilaciclib) Sales Force - G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, NC, December 16, 2021 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will hire |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 (December 15, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorp |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 (November 1, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorpor |
|
| November 3, 2021 |
EXHIBIT 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[* * *]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), date |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 3, 2021 |
G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan. Exhibit 10.1 G1 THERAPEUTICS, INC. 2021 SALES FORCE INDUCEMENT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this G1 Therapeutics, Inc. 2021 Sales Force Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its beh |
|
| November 3, 2021 |
Exhibit 99.1 G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA? (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA? - Initiation of Two New Phase 2 Trials Expected in the Fourt |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2021 (October 13, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorpor |
|
| September 15, 2021 |
Exhibit 99.1 G1 Therapeutics Announces New Supplemental COSELA? (Trilaciclib) Sales Force - New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities - RESEARCH TRIANGLE PARK, NC, September 15, 2021 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to supplement the Boehrin |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 (September 9, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incor |
|
| August 4, 2021 |
Exhibit 99.1 G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights - Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA? (trilaciclib) - - Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer (TNBC) Evaluating the Survival Benefit of COSELA Compared with Placebo - - Initiated Randomized Phase |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 4, 2021 |
EXHIBIT 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), is made and entered into effective as of July 28, 2021 (the ?Effective Date?), by and between G1 Therapeutics, Inc., a Delaware corporation (the ?Company?), and Andrew Perry (?Employee?). 1.EMPLOYMENT; DUTIES. The Company agrees to employ Employee as its Chief Commercial Officer, and Employee agrees to accept such emplo |
|
| August 4, 2021 |
Exhibit 10.3 Scientific, Clinical, and Regulatory Advisor AGREEMENT Seth Rudnick, M.D. 13 Aronimink Lane, #5341 Pinehurst, NC 28374 Dear Dr. Rudnick: This SCIENTIFIC, CLINICAL, AND REGULATORY ADVISOR AGREEMENT (the ''Agreement"), is effective as of July 1, 2021 (the "Effective Date"), by and between G1 Therapeutics, Inc., a Delaware corporation (the "Company"), and you. This Agreement replaces tha |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 (July 27, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation |
|
| August 2, 2021 |
EXHIBIT 99.1 G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer - Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - RESEARCH TRIANGLE PARK, N.C., August 2, 2021 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO). Mr. Perry replace |
|
| July 2, 2021 |
Form of Subordinated Indenture EX-4.8 4 d160928dex48.htm EX-4.8 Exhibit 4.8 G1 THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a |
|
| July 2, 2021 |
Powers of Attorney (included on the signature page of the initial registration statement). Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2021 (June 30, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| July 2, 2021 |
Exhibit 1.2 G1 THERAPEUTICS, INC. COMMON STOCK (par value $0.0001 per share) SALES AGREEMENT July 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: G1 Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees th |
|
| July 2, 2021 |
Exhibit 4.7 G1 THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04( |
|
| July 2, 2021 |
EX-3.1 2 d194551dex31.htm EX-3.1 EXHIBIT 3.1 CERTIFICATE OF CORRECTION TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF G1 THERAPEUTICS, INC. June 30, 2021 The undersigned hereby certifies that: 1. The name of this corporation is G1 Therapeutics, Inc. 2. An Amended and Restated Certificate of Incorporation (the “Certificate”) of this corporation was filed to amend and restate the provis |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 (June 17, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| June 21, 2021 |
EXHIBIT 10.1 G1 THERAPEUTICS, INC. SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors of G1 Therapeutics, Inc. (the ?Company?) has approved the following Second Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) which establishes compensation to be paid to non-employee directors of the Company, effective as of June 17, 2021 (the |
|
| June 21, 2021 |
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors EXHIBIT 99.1 G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors RESEARCH TRIANGLE PARK, N.C., June 18, 2021 ? G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors. With more than 30 years of experience in the life sciences industry, she has a proven track record of leading life sci |
|
| May 5, 2021 |
Quarterly Report - GTHX-Q1-2021 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 5, 2021 |
Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of March 31, 2021, is entered into by and among G1 THERAPEUTICS, INC., a Delaware corporation, and each of its Subsidiaries (hereinafter collectively referred to as the ?Borrower?), the several banks and other financial institutions or entit |
|
| May 5, 2021 |
EX-99.1 2 d342613dex991.htm EX-99.1 Exhibit 99.1 G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights - G1’s COSELA™ (trilaciclib), the Only FDA-Approved Proactive Multilineage Myeloprotection Therapy, Approved on February 12, 2021 and Commercially Available as of March 2, 2021 - - Strong Total Revenue of $14.2 Million Included $0.6 Million from Initial Sales of |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission File |
|
| April 28, 2021 |
DEF 14A 1 d122680ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2021 (April 21, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporatio |
|
| March 30, 2021 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology - COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors - RESEARCH TRIANGLE PARK, NC, March 25, 2021 – G1 Therapeutics, Inc. (Nasdaq |
|
| March 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 (March 25, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporatio |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 25, 2021 |
EXHIBIT 99.2 Option No. G1 THERAPEUTICS, INC. Non-Qualified Stock Option Grant Notice 1.??Name and Address of Participant: Soma Gupta 321 West 55th Street New York, New York 10019 2.??Date of Option Grant: March 31, 2020 3.??Maximum Number of Shares for which this Option is exercisable: 300,000 4.??Exercise (purchase) price per share: $11.02 5.??Option Expiration Date: March 31, 2030 6.??Vesting S |
|
| March 25, 2021 |
EXHIBIT 99.3 Option No. G1 THERAPEUTICS, INC. Non-Qualified Stock Option Grant Notice 1. Name and Address of Participant: William C. Roberts, Jr. 37 S Iroquois Ln Chester Springs, PA 19425 2. Date of Option Grant: January 4, 2021 3. Maximum Number of Shares for which this Option is exercisable: 50,000 4. Exercise (purchase) price per share: $18.07 5. Option Expiration Date: January 4, 2031 6. Vest |
|
| March 25, 2021 |
Form of Stock Option Agreement under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan EXHIBIT 99.5 Option No. G1 THERAPEUTICS, INC. Stock Option Grant Notice Non-Qualified Stock Option Grant under the Company?s 2021 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Maximum Number of Shares for which this Option is exercisable: 4. Exercise (purchase) price per share: 5. Option Expiration Date: 6. Vesting Start Date: 7. Vesting Schedule: |
|
| March 25, 2021 |
EXHIBIT 99.6 Restricted Stock Unit No. G1 Therapeutics, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company?s 2021 Inducement Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted Stock Unit Award |
|
| February 24, 2021 |
Annual Report - GTHX 10-K 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38096 G1 THERAPEUTICS |
|
| February 24, 2021 |
G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan EX-10.7 3 gthx-ex107432.htm EX-10.7 Exhibit 10.7 G1 THERAPEUTICS, INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to ac |
|
| February 24, 2021 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights - G1’s COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March - - Launch Underway, including Medical Affairs, Promotional, and Educational Activities |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2021 |
Description of Securities of the Registrant. EX-4.2 2 gthx-ex426.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated by-laws are summaries of material terms and provisions and are qualified by reference to |
|
| February 16, 2021 |
EX-99.1 Exhibit 99.1 FDA Approves G1 Therapeutics’ COSELATM (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression - COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective effic |
|
| February 16, 2021 |
Optimizing Chemotherapy, Advancing Survival February 16, 2021 Exhibit 99.2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumsta |
|
| February 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 (February 12, 2021) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorp |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 G1 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3621LQ109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: G1 Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 3621LQ109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* G1 Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 3621LQ109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 11, 2021 |
EX-99.1 Optimizing Chemotherapy, Advancing Survival 39th Annual J.P. Morgan Healthcare Conference January 2021 Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions r |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| November 4, 2020 |
Exhibit 10.2 September 29, 2020 John E. Bailey, Jr. 11316 Moonsprite Way Raleigh, NC 27614 Re:Senior Advisor Agreement Dear Jack: I am providing this letter agreement (the “Senior Advisor Agreement”) to confirm the terms of your senior advisor engagement with G1 Therapeutics, Inc. (the “Company”). We appreciate all of your efforts and contributions to the Company as a member of our Board of Direct |
|
| November 4, 2020 |
Quarterly Report - GTHX-Q3-2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 4, 2020 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update - New Drug Application (NDA) for trilaciclib in small cell lung cancer accepted for Priority Review with a PDUFA action date of February 15, 2021 - Announced CEO succession plan in evolution to commercial-stage company - Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIAN |
|
| November 4, 2020 |
Exhibit 10.3 September 29, 2020 Mark A. Velleca, M.D., Ph.D. 1306 N. Duke Street Durham, NC 27701 Re:Senior Advisor Agreement Dear Mark: I am providing this letter agreement (the “Agreement”) to confirm the terms of your senior advisor engagement with G1 Therapeutics, Inc. (the “Company”). We appreciate all of your efforts and contributions to the Company, and look forward to entering into this en |
|
| November 4, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into effective as of September 29, 2020 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and John E. Bailey, Jr. (“Employee”). 1.EMPLOYMENT; DUTIES. The Company agrees to employ Employee as its President and Chief Executive Officer, and Employee ag |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission |
|
| September 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 (September 24, 2020) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of inco |
|
| September 30, 2020 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics Announces Chief Executive Officer Succession Plan - Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors - Jack Bailey to succeed Dr. Velleca as Chief Executive Officer effective January 1, 2021 RESEARCH TRIANGLE PARK, N.C., September 30, 2020 – G1 Therapeutics, Inc. (Nasdaq: GT |
|
| September 9, 2020 |
GTHX / G1 Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* G1 Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 3621LQ109 (CUSIP Number) August 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| August 5, 2020 |
Exhibit 10.1 Scientific, Clinical, and Regulatory Advisor AGREEMENT Seth Rudnick, M.D. 13 Aronimink Lane, #5341 Pinehurst, NC 28374 Dear Dr. Rudnick: This SCIENTIFIC, CLINICAL, AND REGULATORY ADVISOR AGREEMENT (the ''Agreement"), is effective as of July 1, 2020 (the "Effective Date"), by and between G1 Therapeutics, Inc., a Delaware corporation (the "Company"), and you. This Agreement replaces tha |
|
| August 5, 2020 |
Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. CO-PROMOTION AGREEMENT by and between G1 THERAPEUTICS, INC. and BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. June 29, 2020 CO-PRO |
|
| August 5, 2020 |
EXHIBIT 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of May 29, 2020 and is entered into by and am |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 5, 2020 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update - Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trilaciclib in China and global out-licensing of lerociclib net a combined $40 million in upfront payments, up to $486 |
|
| August 5, 2020 |
Quarterly Report - GTHX-Q2-2020 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| June 30, 2020 |
EX-99.1 EXHIBIT 99.1 G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico - Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements - G1 to retain full development and commercialization rights and book revenue for trilaciclib - New Drug Applic |
|
| June 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 (June 29, 2020) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 (June 11, 2020) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 (May 29, 2020) G1 THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38096 26-3648180 (State or other jurisdiction of incorporation) ( |
